Assessing health-related quality of life in gynecologic oncology: A systematic review of questionnaires and their ability to detect clinically important differences and change

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 664-684

  Luckett, Tim ^a   King, Madeleine ^a   Butow, Phyllis ^a   Friedlander, Michael ^b,c   Paris, Tim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c Australia and New Zealand Gynaecologic Oncology Group Coordination Centre   (Australia)

Author keywords

Gynecologic cancer; Psychometric properties; Quality of life; Questionnaires; Sensitivity and responsiveness

Indexed keywords

ARTICLE; ENDOMETRIUM CANCER; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE C30; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE CX24; EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE OV28; FUNCTIONAL ASSESSMENT OF CANCER THERAPY ANEMIA; FUNCTIONAL ASSESSMENT OF CANCER THERAPY CX; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL; FUNCTIONAL ASSESSMENT OF CANCER THERAPY O; FUNCTIONAL ASSESSMENT OF CANCER THERAPY V; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS AND THERAPY; GYNECOLOGIC CANCER; GYNECOLOGY ONCOLOGY GROUP; HUMAN; INTERMETHOD COMPARISON; OVARY CANCER; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE OVARIAN CANCER PATIENT VERSION; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; SENSITIVITY AND SPECIFICITY; SHORT FORM 12; SHORT FORM 36; SHORT FORM CANCER REHABILITATION EVALUATION SYSTEM; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; VALIDATION PROCESS; VULVA CANCER;

EVALUATION STUDIES AS TOPIC; FEMALE; GENITAL NEOPLASMS, FEMALE; HEALTH STATUS; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 77952248227     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181dad379     Document Type: Article

References (62)

1. Gondek K, Sagnier P-P, Gilchrist K, et al. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels. J Clin Oncol. 2007;25:5087-5093.
2. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95: S247-S257.
3. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist. 2002;7:11-19.
4. Boling W, Fouladi RT, Basen-Engquist K. Health-related quality of life in gynecological oncology: instruments and psychometric properties. Int J Gynecol Cancer. 2003;13:5-14.
5. Cull A, Howat S, Greimel E, et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer. 2001;37:47-53.
6. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Ovarian. J Clin Oncol. 2001;19:1809-1817.
7. Ferrans CE. Definitions and conceptual models of quality of life. In: J Lipscomb CCG, Snyder C, eds. Outcomes Research in Cancer: Measures, Methods, and Applications. Cambridge, UK: Cambridge University Press; 2005:14-30.
8. Robinson PG, Carr AJ, Higginson IJ. How to choose a quality of life measure. In: Carr AJ, Higginson IJ, Robinson PG, eds. Quality of Life. London: BMJ Books; 2003:88-100.
9. Lohr K. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res. 2002;11:193-205.
10. Fayers PM, Machin D. Quality of Life: The Assessment, Analysis and Interpretation of Patient-Reported Outcomes. 2nd ed. Chichester, UK: John Wiley and Sons, Ltd; 2007.
11. Wiebe S, Guyatt G, Weaver B, et al. Comparative responsiveness of generic and specific quality-of-life instruments. J Clinl Epidemiol. 2003;56:52-60.
12. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
13. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
14. Holzner B, Bode RK, Hahn EA, et al. Equating EORTC QLQ-C30 and FACT-G scores and its use in oncological research. Eur J Cancer. 2006;42:3169-3177.
15. Gil KM, Frasure HE, Hopkins MP, et al. Effect of method of administration on longitudinal assessment of quality of life in gynecologic cancer: an exploratory study. Health Qual Life Outcomes. 2005;3:6.
16. Blazeby JM, Kavadas V, Vickery CW, et al. A prospective comparison of quality of life measures for patients with esophageal cancer. Qual Life Res. 2005;14:387-393.
17. Rodary C, Pezet-Langevin V, Garcia-Acosta S, et al. Patient preference for either the EORTC QLQ-C30 or the FACIT Quality of Life (QOL) measures: a study performed in patients suffering from carcinoma of an unknown primary site (CUP). Eur J Cancer. 2004;40:521-528.
18. Jones GL, Ledger W, Bonnett TJ, et al. The impact of treatment for gynecological cancer on health-related quality of life (HRQoL): a systematic review. Am J Obstet Gynecol. 2006;194:26-42.
19. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
20. Jaeschke RJ, Singer J, Guyatt G. Measurement of health status: ascertaining the minimally clinically important difference. Control Clin Trials. 1989;10:407-415.
21. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582-592.
22. Beaton DE. Simple as possible? Or too simple? Possible limits to the universality of the one half standard deviation [comment]. Med Care. 2003;41:593-596.
23. Osoba D, Bezjak A, Brundage M, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005;41:280-287.
24. Webster K, Cella D, Yost KJ. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003:1-79. http://www.hqlo.com/ content/1/1/.
25. Ware JE, Kosinski MA, Bjorner JB, et al. User's Manual for the SF-36v2 Health Survey. 2nd ed. Lincoln, RI: Quality Metric Inc; 2007.
26. Fayers PM, Aaronson NK, Bjordal K, et al. EORTC QLQ-C30 Scoring Manual. Brussels: EORTC; 1995.
27. Cohen J. Statistical Power Analysis for the Behavioural Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
28. Ferrell B, Cullinane CA, Ervine K, et al. Perspectives on the impact of ovarian cancer: women's views of quality of life. Oncoly Nurs Forum Online. 2005;32:1143-1149.
29. von Gruenigen VE, Gil KM, Frasure HE, et al. The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol. 2005;193:1369-1375.
30. Bradley S, Rose S, Lutgendorf S, et al. Quality of life and mental health in cervical and endometrial cancer survivors. Gynecol Oncol. 2006;100:479-486.
31. Gil KM, Gibbons HE, Jenison EL, et al. Baseline characteristics influencing quality of life in women undergoing gynecologic oncology surgery. Health Qual Life Outcomes. 2007;5:25.
32. von Gruenigen VE, Frasure HE, Jenison EL, et al. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol. 2006;103:120-126.
33. Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol. 2005;23:7428-7436.
34. Ware J Jr, Kosinski M, Keller SD. A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34:220-233.
35. Greimel E, Bottomley A, Cull A, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer [published correction appears in Eur J Cancer. 2003;39(17):2570].
36. Eur J Cancer. 2003;39:1402-1408.
37. Greimel ER, Kuljanic Vlasic K, Waldenstrom A-C, et al. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer. 2006;107:1812-1822.
38. Courneya KS, Karvinen KH, Campbell KL, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol. 2005;97:422-430.
39. Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741-748.
40. Huang HQ, Brady MF, Cella D, et al. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007;17:387-393.
41. Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:437-443.
42. Doyle C, Crump M, Pintilie M, et al. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol. 2001;19:1266-1274.
43. Cheung Y-B, Goh C, Thumboo J, et al. Variability and sample size requirements of quality-of-life measures: a randomized study of three major questionnaires [comment]. J Clin Oncol. 2005;23:4936-4944.
44. Janda M, Obermair A, Cella D, et al. The Functional Assessment of Cancer-Vulvar: reliability and validity. Gynecol Oncol. 2005;97:568-575.
45. Ashing-Giwa KT, Kim J, Tejero JS. Measuring quality of life among cervical cancer survivors: preliminary assessment of instrumentation validity in a cross-cultural study. Qual Life Res. 2008;17:147-157.
46. Butler L, Bacon M, Carey M, et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol. 2004;22:2461-2468.
47. Jensen PT, Klee MC, Thranov I, et al. Validation of a questionnaire for self-assessment of sexual function and vaginal changes after gynaecological cancer. Psychooncology. 2004;13:577-592.
48. Liavaag AH, Dorum A, Fossa SD, et al. Controlled study of fatigue, quality of life, and somatic and mental morbidity in epithelial ovarian cancer survivors: how lucky are the lucky ones? J Clin Oncol. 2007;25:2049-2056.
49. Hawighorst-Knapstein S, Fusshoeller C, Franz C, et al. The impact of treatment for genital cancer on quality of life and body image-results of a prospective longitudinal 10-year study. Gynecol Oncol. 2004;94:398-403.
50. Zullo F, Palomba S, Russo T, et al. A prospective randomized comparison between laparoscopic and laparotomic approaches in women with early stage endometrial cancer: a focus on the quality of life. Am J Obstet Gynecol. 2005;193:1344-1352.
51. Stevinson C, Faught W, Steed H, et al. Associations between physical activity and quality of life in ovarian cancer survivors. Gynecol Oncol. 2007;106:244-250.
52. Liavaag AH, Dorum A, Bjoro T, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecol Oncol. 2008;108:348-354.
53. Bye A, Trope C, Loge JH, et al. Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy-evaluation of long-term effects of diagnosis and treatment. Acta Oncol. 2000;39:173-180.
54. Zhao H, Kanda K, Liu SJ, et al. Evaluation of quality of life in Chinese patients with gynaecological cancer: assessments by patients and nurses. Int J Nurs Pract. 2003;9:40-48.
55. Hartenbach EM, Harris LS, Bailey HH, et al. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer [comment]. Cancer J Sci Am. 1999;5:348-355.
56. Capelli G, De Vincenzo RI, Addamo A, et al. Which dimensions of health-related quality of life are altered in patients attending the different gynecologic oncology health care settings? Cancer. 2002;95:2500-2507.
57. Roos EJ, de Graeff A, van Eijkeren MA, et al. Quality of life after pelvic exenteration. Gynecol Oncol. 2004;93:610-614.
58. Bruner DW, Barsevick A, Tian C, et al. Randomized trial results of quality of life comparing whole abdominal irradiation and combination chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. Qual Life Res. 2007;16:89-100.
59. Ding Y, Zhu Y-L, Zhang M-F. Quality of life of Chinese patients with ovarian malignancies during chemotherapy under condition of no recurrence. Cancer Nurs. 2007;30:243-251.
60. Bezjak A, Tu D, Bacon M, et al. Quality of life in ovarian cancer patients: comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol. 2004;22:4595-4603.
61. Wenzel L, Huang HQ, Monk BJ, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2005;23:5605-5612.
62. Chan YM, Ngan HY, Li BY, et al. A longitudinal study on quality of life after gynecologic cancer treatment. Gynecol Oncol. 2001;83:10-19.